JP2004163388A - マーカーの選択 - Google Patents
マーカーの選択 Download PDFInfo
- Publication number
- JP2004163388A JP2004163388A JP2003095679A JP2003095679A JP2004163388A JP 2004163388 A JP2004163388 A JP 2004163388A JP 2003095679 A JP2003095679 A JP 2003095679A JP 2003095679 A JP2003095679 A JP 2003095679A JP 2004163388 A JP2004163388 A JP 2004163388A
- Authority
- JP
- Japan
- Prior art keywords
- gene
- portfolio
- expression
- relationship
- markers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003550 marker Substances 0.000 title claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 105
- 230000014509 gene expression Effects 0.000 claims abstract description 61
- 238000000034 method Methods 0.000 claims abstract description 51
- 238000004422 calculation algorithm Methods 0.000 claims description 10
- 230000035945 sensitivity Effects 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 4
- 238000005259 measurement Methods 0.000 abstract description 18
- 201000010099 disease Diseases 0.000 abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 21
- 238000002493 microarray Methods 0.000 description 16
- 230000001105 regulatory effect Effects 0.000 description 11
- 238000004393 prognosis Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 238000010837 poor prognosis Methods 0.000 description 5
- 238000012340 reverse transcriptase PCR Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 239000013610 patient sample Substances 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000010187 selection method Methods 0.000 description 3
- 238000000528 statistical test Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 101150094765 70 gene Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000003040 circulating cell Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000000683 nonmetastatic effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101150106899 28 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000012775 microarray technology Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Complex Calculations (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36879002P | 2002-03-29 | 2002-03-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004163388A true JP2004163388A (ja) | 2004-06-10 |
| JP2004163388A5 JP2004163388A5 (enExample) | 2006-03-16 |
Family
ID=27805329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003095679A Pending JP2004163388A (ja) | 2002-03-29 | 2003-03-31 | マーカーの選択 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20030194734A1 (enExample) |
| EP (1) | EP1349104A3 (enExample) |
| JP (1) | JP2004163388A (enExample) |
| KR (1) | KR20030078803A (enExample) |
| CN (1) | CN1495272A (enExample) |
| AR (1) | AR039212A1 (enExample) |
| AU (1) | AU2003203529A1 (enExample) |
| BR (1) | BR0303080A (enExample) |
| CA (1) | CA2422309A1 (enExample) |
| MX (1) | MXPA03002865A (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008528024A (ja) * | 2005-01-31 | 2008-07-31 | ディジタルジェノミクスインコーポレーション | 肺癌診断用マーカー遺伝子 |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1361433A3 (en) * | 2002-04-09 | 2005-02-23 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Method for estimating therapeutic efficacy of tumor necrosis factor (TNF) |
| US20040191782A1 (en) * | 2003-03-31 | 2004-09-30 | Yixin Wang | Colorectal cancer prognostics |
| US20050186577A1 (en) | 2004-02-20 | 2005-08-25 | Yixin Wang | Breast cancer prognostics |
| CA2575986A1 (en) * | 2004-08-02 | 2006-02-09 | Banyu Pharmaceutical Co., Ltd. | Method of assuming drug sensitivity to cdk4 inhibitor |
| US20060252057A1 (en) * | 2004-11-30 | 2006-11-09 | Mitch Raponi | Lung cancer prognostics |
| KR100690250B1 (ko) * | 2005-01-31 | 2007-03-12 | 디지탈 지노믹스(주) | 폐암 진단용 마커 |
| US20070037186A1 (en) | 2005-05-20 | 2007-02-15 | Yuqiu Jiang | Thyroid fine needle aspiration molecular assay |
| IL177006A0 (en) | 2005-08-02 | 2006-12-10 | Veridex Llc | Predicting bone relapse of breast cancer |
| US20070130694A1 (en) * | 2005-12-12 | 2007-06-14 | Michaels Emily W | Textile surface modification composition |
| US20070207467A1 (en) | 2006-03-01 | 2007-09-06 | Ming Xu | Detection of lymph node metastasis from gastric carcinoma |
| BRPI0708534A2 (pt) * | 2006-03-03 | 2011-05-31 | Veridex Llc | ensaio molecular para prognosticar a recorrência de cáncer do cólon dukes b |
| WO2008058018A2 (en) | 2006-11-02 | 2008-05-15 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
| US20080306881A1 (en) * | 2006-12-22 | 2008-12-11 | X-Shares Advisors Llc | Portfolio selection for custom indices of public securities based on state of domicile of issuing company |
| US20080206777A1 (en) | 2007-02-27 | 2008-08-28 | Nuclea Biomarkers, Llc | Gene and protein expression profiles associated with the therapeutic efficacy of EGFR-TK inhibitors |
| EP2240609A4 (en) * | 2008-01-22 | 2011-08-03 | Veridex Llc | MOLECULAR CLASSIFICATION OF COLONCARCINOMA STADIAS II AND III AND FORECAST |
| US20110059464A1 (en) | 2008-04-08 | 2011-03-10 | Muraca Patrick J | Biomarker Panel For Prediction Of Recurrent Colorectal Cancer |
| CA2725978A1 (en) | 2008-05-28 | 2009-12-03 | Genomedx Biosciences, Inc. | Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer |
| US10407731B2 (en) | 2008-05-30 | 2019-09-10 | Mayo Foundation For Medical Education And Research | Biomarker panels for predicting prostate cancer outcomes |
| EP2730662A1 (en) | 2008-11-12 | 2014-05-14 | Caris Life Sciences Luxembourg Holdings | Methods and systems of using exosomes for determining phenotypes |
| US10236078B2 (en) | 2008-11-17 | 2019-03-19 | Veracyte, Inc. | Methods for processing or analyzing a sample of thyroid tissue |
| US9495515B1 (en) | 2009-12-09 | 2016-11-15 | Veracyte, Inc. | Algorithms for disease diagnostics |
| US9074258B2 (en) | 2009-03-04 | 2015-07-07 | Genomedx Biosciences Inc. | Compositions and methods for classifying thyroid nodule disease |
| CA2753916C (en) | 2009-04-29 | 2020-08-25 | Genomedx Biosciences Inc. | Systems and methods for expression-based classification of thyroid tissue |
| US8669057B2 (en) | 2009-05-07 | 2014-03-11 | Veracyte, Inc. | Methods and compositions for diagnosis of thyroid conditions |
| US10446272B2 (en) | 2009-12-09 | 2019-10-15 | Veracyte, Inc. | Methods and compositions for classification of samples |
| US9128101B2 (en) | 2010-03-01 | 2015-09-08 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarkers for theranostics |
| BR112012025593A2 (pt) | 2010-04-06 | 2019-06-25 | Caris Life Sciences Luxembourg Holdings | biomarcadores em circulação para doença |
| US20130267443A1 (en) | 2010-11-19 | 2013-10-10 | The Regents Of The University Of Michigan | ncRNA AND USES THEREOF |
| EP2791359B1 (en) | 2011-12-13 | 2020-01-15 | Decipher Biosciences, Inc. | Cancer diagnostics using non-coding transcripts |
| AU2013302365B2 (en) | 2012-08-16 | 2019-03-21 | Mayo Foundation For Medical Education And Research | Cancer diagnostics using biomarkers |
| US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
| US12297505B2 (en) | 2014-07-14 | 2025-05-13 | Veracyte, Inc. | Algorithms for disease diagnostics |
| WO2016073768A1 (en) | 2014-11-05 | 2016-05-12 | Veracyte, Inc. | Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data |
| EP3504348B1 (en) | 2016-08-24 | 2022-12-14 | Decipher Biosciences, Inc. | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy |
| CA3050984A1 (en) | 2017-01-20 | 2018-07-26 | Decipher Biosciences, Inc. | Molecular subtyping, prognosis, and treatment of bladder cancer |
| CA3055925A1 (en) | 2017-03-09 | 2018-09-13 | Decipher Biosciences, Inc. | Subtyping prostate cancer to predict response to hormone therapy |
| CA3062716A1 (en) | 2017-05-12 | 2018-11-15 | Decipher Biosciences, Inc. | Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness |
| US11217329B1 (en) | 2017-06-23 | 2022-01-04 | Veracyte, Inc. | Methods and systems for determining biological sample integrity |
| WO2019028285A2 (en) | 2017-08-04 | 2019-02-07 | Genomedx, Inc. | USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR1000347B (el) * | 1988-12-21 | 1992-06-25 | Ortho Diagnostic Systems Inc | Μεθοδος παραγωγης νουκλεοτιδικων ανιχνευτων χρησιμοποιωντας ενα συμπληρωμα γεφυρωσεως. |
| US6350576B1 (en) * | 1994-12-20 | 2002-02-26 | Cold Spring Harbor Laboratory | Cancer detection probes |
| US5972614A (en) * | 1995-12-06 | 1999-10-26 | Genaissance Pharmaceuticals | Genome anthologies for harvesting gene variants |
| US6275814B1 (en) * | 1996-11-27 | 2001-08-14 | Investment Strategies Network | Investment portfolio selection system and method |
| US6003018A (en) * | 1998-03-27 | 1999-12-14 | Michaud Partners Llp | Portfolio optimization by means of resampled efficient frontiers |
| US6882990B1 (en) * | 1999-05-01 | 2005-04-19 | Biowulf Technologies, Llc | Methods of identifying biological patterns using multiple data sets |
| US6401043B1 (en) * | 1999-04-26 | 2002-06-04 | Variagenics, Inc. | Variance scanning method for identifying gene sequence variances |
| US6175824B1 (en) * | 1999-07-14 | 2001-01-16 | Chi Research, Inc. | Method and apparatus for choosing a stock portfolio, based on patent indicators |
| EP1196027A4 (en) * | 1999-07-15 | 2004-12-22 | Res Dev Foundation | CORTICOTROPIN RELEASE FACTOR-2 RECEPTOR 2 MOUSE AND USES THEREOF |
-
2003
- 2003-03-21 US US10/394,087 patent/US20030194734A1/en not_active Abandoned
- 2003-03-28 CA CA002422309A patent/CA2422309A1/en not_active Abandoned
- 2003-03-28 AU AU2003203529A patent/AU2003203529A1/en not_active Abandoned
- 2003-03-28 BR BR0303080-6A patent/BR0303080A/pt not_active IP Right Cessation
- 2003-03-29 CN CNA031312047A patent/CN1495272A/zh active Pending
- 2003-03-29 KR KR10-2003-0019839A patent/KR20030078803A/ko not_active Withdrawn
- 2003-03-31 JP JP2003095679A patent/JP2004163388A/ja active Pending
- 2003-03-31 MX MXPA03002865A patent/MXPA03002865A/es unknown
- 2003-03-31 EP EP03252027A patent/EP1349104A3/en not_active Withdrawn
- 2003-04-01 AR ARP030101133A patent/AR039212A1/es not_active Application Discontinuation
-
2009
- 2009-07-01 US US12/496,399 patent/US20100009371A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008528024A (ja) * | 2005-01-31 | 2008-07-31 | ディジタルジェノミクスインコーポレーション | 肺癌診断用マーカー遺伝子 |
| US7871774B2 (en) | 2005-01-31 | 2011-01-18 | Digital Genomics Inc. | Markers for the diagnosis of lung cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20030078803A (ko) | 2003-10-08 |
| US20100009371A1 (en) | 2010-01-14 |
| AU2003203529A1 (en) | 2003-10-23 |
| BR0303080A (pt) | 2004-02-17 |
| US20030194734A1 (en) | 2003-10-16 |
| EP1349104A3 (en) | 2004-01-02 |
| AR039212A1 (es) | 2005-02-09 |
| EP1349104A2 (en) | 2003-10-01 |
| CA2422309A1 (en) | 2003-09-29 |
| MXPA03002865A (es) | 2004-08-11 |
| CN1495272A (zh) | 2004-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4409845B2 (ja) | 癌診断パネル | |
| JP2004163388A (ja) | マーカーの選択 | |
| AU2013266419B2 (en) | NANO46 genes and methods to predict breast cancer outcome | |
| CN101356532B (zh) | 基于基因的算法型癌症预后 | |
| JP4913331B2 (ja) | 結腸直腸癌の予後 | |
| US8183353B2 (en) | Breast cancer prognostics | |
| JP2007049991A (ja) | 乳癌の骨への再発の予測 | |
| JP2004537261A (ja) | 候補遺伝子のアレイを用いた原発性乳がんの遺伝子発現プロファイリング | |
| EP2304631A1 (en) | Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer | |
| WO2006127537A2 (en) | Thyroid fine needle aspiration molecular assay | |
| JP5089993B2 (ja) | 乳癌の予後診断 | |
| JP2009153521A (ja) | 結腸直腸癌の評価 | |
| JP2011509689A (ja) | Ｉｉ及びｉｉｉ期結腸癌の分子病期分類並びに予後診断 | |
| JP2009153522A (ja) | 結腸直腸癌の評価 | |
| CA2912445A1 (en) | Methods to predict risk of recurrence in node-positive early breast cancer | |
| EP1367138B1 (en) | Markers for breast cancer prognosis | |
| US20050186577A1 (en) | Breast cancer prognostics | |
| US20170183738A1 (en) | Process, Apparatus or System and Kit for Classification of Tumor Samples of Unknown and/or Uncertain Origin and Use of Genes of the Group of Biomarkers | |
| EP1683862B1 (en) | Microarray for assessing neuroblastoma prognosis and method of assessing neuroblastoma prognosis | |
| EP1679382A2 (en) | Panel of nucleic acid sequences for cancer diagnosis | |
| Calistri | Clinical Applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060123 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060123 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20070510 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070522 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071120 |